Scientific Advice - Protocol Assistance

Peter Embley appointed as
Chief Regulatory Officer.

Pete joins Arriello to lead it’s Regulatory Affairs team.

A focus on building up further expertise with new Principal Consultants, and our Clinical Regulatory Strategy and solutions.

Pete comes with over 24 years of experience working across the Pharmaceutical, CRO and Consulting Industries.

Grounded in UK and European regulatory activities, and in particular, developing and executing strategies for generic and early-stage development programs, his responsibilities have included, but not limited to; Agency Scientific Advice, feasibility of accelerated tools such as EMA-PRIME, MHRA-ILAP, CMC, PIP, Market-Access and MAA due-diligence.

More recently, Pete has supported US IND/EU CTA and Chinese IND submissions, leading a team for the development and execution of Early (& Post-Trial) Access Programs.

A keen advocate for professional regulatory development, Pete is a Fellow of the regulatory association (TOPRA), and a Module Leader on the TOPRA Regulatory Affairs MSc. course.  Pete is also a regular lecturer at the University of Limerick.

Pete will report to Arriello’s COO Anna Lukyanova.

Latest news.

View all
Peter Embley joins Arriello to lead it’s Regulatory Affairs team and comes with over 24 years of experience working across the Pharmaceutical, CRO and Consulting Industries.
Pete Embley News
Arriello welcomes high-profile Pharmacovigilance leader Prabjot Hunjan as Director of Global Drug Safety.
Prabjot Hunjan Official
The new space will cater for our growing number of operational and commercial #TeamYellow staff as we continue to build our physical presence in different locations.
Lisbon, Portugal